ライフサイエンスコーパス: antiretrovirals

1 realize the full public health potential of antiretrovirals.

2 nce of latent genomes despite treatment with antiretrovirals.

3 and imatinib pharmacokinetics in patients on antiretrovirals.

4 ficiency virus (HIV)-positive individuals on antiretrovirals.

5 IV infection is successfully controlled with antiretrovirals.

6 ese mutations affect susceptibility to other antiretrovirals.

7 nteractions were observed with other studied antiretrovirals.

8 ardiovascular events associated with certain antiretrovirals.

9 ly predicts the combined effects of multiple antiretrovirals.

10 ompared to contemporary clinically-evaluated antiretrovirals.

11 to consider drug-drug interactions with the antiretrovirals.

12 re likely to normalize in those treated with antiretrovirals.

13 ing cART, without having previously received antiretrovirals.

14 ents with limited or no previous exposure to antiretrovirals.

15 genotypic evaluation of HIV-1 resistance to antiretrovirals.

16 tance to nucleoside (NRTI) and nonnucleoside antiretrovirals.

17 None of the responses were attributable to antiretrovirals.

18 ruses, a goal not easily achieved with other antiretrovirals.

19 erse pregnancy outcomes in women who receive antiretrovirals.

20 All mothers were receiving antiretrovirals.

21 us were adjusted to account for detection of antiretrovirals.

22 an harbor mutations conferring resistance to antiretrovirals.

23 ited data are available for long-acting (LA) antiretrovirals.

24 ong-term disease despite the adequate use of antiretrovirals.

25 nce monitoring for patients on all TFV-based antiretrovirals.

26 verwhelmed by high MOI than other classes of antiretrovirals.

27 direct-acting antiviral agents (DAA) and HIV antiretrovirals.

28 received appropriate regimens, including new antiretrovirals.

29 proving treatment outcomes is in long-acting antiretrovirals.

30 re likely to normalize in those treated with antiretrovirals.

31 of drug resistance than other commonly used antiretrovirals.

32 t a novel drug target for the development of antiretrovirals.

33 ical D:A:D score and potentially nephrotoxic antiretrovirals.

34 ollow-up liver function measurements were on antiretrovirals (85% with efavirenz, 13% with nevirapine

35 -exposed uninfected children were exposed to antiretrovirals (88% to maternal triple antiretroviral t

36 y endothelial cells were pretreated with the antiretrovirals abacavir sulphate (ABC), tenofovir disop

37 findings suggest that nucleoside-containing antiretrovirals administered via recommended protocols d

38 clinicians to weigh the benefits of certain antiretrovirals against the risk of CKD and to identify

39 Antiretrovirals alone decreased concentrations of some B

40 Although antiretrovirals alone had no significant effect on ribof

41 eople who were virologically suppressed with antiretrovirals also showed type 1 IFN refractoriness.

42 We assessed the effect of (1) individual antiretrovirals and (2) an individual TL-polygenic risk

43 Antiretrovirals and cytokines/chemokines concentrations

44 Pharmacokinetics of the antiretrovirals and DAAs were characterized when adminis

45 Other antiretrovirals and delivery systems are being evaluated

46 era of long-acting ART, which includes other antiretrovirals and formulations in various stages of cl

47 ess than 200 copies per mL, or not receiving antiretrovirals and had a CD4 T-cell count of greater th

48 creening, patients were either receiving HIV antiretrovirals and had HIV RNA less than 200 copies per

49 After chemotherapy failure, antiretrovirals and interferon-alpha (IFN-alpha) produce

50 Antiretrovirals and LNSs were given to the mothers from

51 Women were assigned to receive antiretrovirals and LNSs, antiretrovirals only, LNSs onl

52 We used data from the Breastfeeding, Antiretrovirals and Nutrition (BAN) clinical trial (cond

53 d blood spots (DBSs) from the Breastfeeding, Antiretrovirals and Nutrition study to evaluate the impa

54 ontrol arm of the Malawi-based Breastfeeding Antiretrovirals and Nutrition Study using multivariable

55 These observations establish a link between antiretrovirals and specific functional effects that pro

56 association between duration of exposure to antiretrovirals and the development of chronic kidney di

57 lood were collected from Children and women: AntiRetrovirals and the Mechanism of Aging (CARMA) cohor

58 IV-negative patients from the Treatment With Antiretrovirals and Their Impact on Positive and Negativ

59 Resistance to newer antiretrovirals and to all antiretrovirals in a class wa

60 Drug-drug interactions between antiretrovirals and tuberculosis drugs are driven mainly

61 many source subjects who reported any use of antiretrovirals and was rare among source subjects who r

62 or more antiretrovirals, including screening antiretrovirals, and 169 (15%) had previous virological

63 associated with the use of dideoxynucleoside antiretrovirals, and its development limits the choice o

64 The Breastfeeding, Antiretrovirals, and Nutrition (BAN) Study was undertake

65 ts infected with HIV from the Breastfeeding, Antiretrovirals, and Nutrition (BAN) study.

66 37 women recruited within the Breastfeeding, Antiretrovirals, and Nutrition study at 2 or 6 wk and 24

67 ected Malawian mothers in the Breastfeeding, Antiretrovirals, and Nutrition study were randomly assig

68 The BAN (Breastfeeding, Antiretrovirals, and Nutrition) Study was a randomized c

69 has been implicated in the toxicity of some antiretrovirals, and these results indicate that mitocho

70 unts, ART regimen, prior use of mono or dual antiretrovirals, and time to ART start, pLLV (3.46 [2.42

71 for protected-class drugs (antineoplastics, antiretrovirals, antidepressants, antipsychotics, antico

72 odeficiency virus (HIV) and others receiving antiretrovirals are at risk for medication errors during

73 Generic antiretrovirals are currently manufactured at very low p

74 helminths on HIV progression in areas where antiretrovirals are not available.

75 High priced medicines such as antiretrovirals are now included.

76 Antiretrovirals are often approved by the Food and Drug

77 Antiretrovirals are standard treatment for HIV-1-positiv

78 The adverse effects of antiretrovirals are well characterized and include lacti

79 Antiretrovirals (ARTs) are the cornerstone for treatment

80 prevention research is focused on combining antiretrovirals (ARV) and progestin contraceptives to pr

81 Preexposure prophylaxis (PrEP) with antiretrovirals (ARV) can prevent human immunodeficiency

82 Antiretrovirals (ARVs) affect bone density and turnover,

83 Interactions between antiretrovirals (ARVs) and transplant immunosuppressant

84 Antiretrovirals (ARVs) are used with great success for b

85 ding adolescents with VLS or with detectable antiretrovirals (ARVs) in blood.

86 Here, we evaluated the detectability of HIV antiretrovirals (ARVs) in hair from a range of drug clas

87 ed that low and heterogeneous penetration of antiretrovirals (ARVs) in lymph nodes can contribute to

88 Research and development (R&D) for pediatric antiretrovirals (ARVs) is a lengthy process and lags con

89 ection, pre-exposure prophylaxis (PrEP) with antiretrovirals (ARVs) is an important tool for combatin

90 progressive infection and administration of antiretrovirals (ARVs) longitudinally influence the tran

91 We observed that individual antiretrovirals (ARVs) modestly altered intestinal T-cel

92 s (PrEP) with overlapping and nonoverlapping antiretrovirals (ARVs) on human immunodeficiency virus (

93 Drug-drug interactions (DDIs) that involve antiretrovirals (ARVs) tend to cause harm if unrecognize

94 Drug-drug interactions (DDIs) involving antiretrovirals (ARVs) tend to cause harm if unrecognize

95 rable active ingredients of microbicides are antiretrovirals (ARVs) that directly target viral entry

96 mothers with HIV, all prenatally exposed to antiretrovirals (ARVs).

97 The guidelines introduce co-formulated antiretrovirals as a preferred regimen, which will likel

98 The efficacy of antiretrovirals as postexposure prophylaxis (PEP) to pre

99 The administration of antiretrovirals before HIV exposure to prevent infection

100 known safety profiles of faldaprevir and the antiretrovirals being examined.

101 interactions between antiepileptic drugs and antiretrovirals, but are also problematic as the treatme

102 ded understanding of catalysis and design of antiretrovirals, but knowledge of the Pol precursor arch

103 clinical trials have proven that the use of antiretrovirals by HIV-infected and at-risk uninfected p

104 Long-acting antiretrovirals can address barriers to HIV pre-exposure

105 As a treatment alternative, long-acting (LA) antiretrovirals can sustain therapeutic drug concentrati

106 e complete control of viral replication with antiretrovirals, cells with integrated HIV-1 provirus ca

107 mproved survival of individuals treated with antiretrovirals, comorbid conditions are increasingly sa

108 ion drug delivery devices delivering topical antiretrovirals could be effective tools in preventing t

109 ght reduce inflammatory complications and/or antiretrovirals could be protective.

110 Long-acting antiretrovirals could provide a useful alternative to da

111 ns between faldaprevir and the commonly used antiretrovirals darunavir/ritonavir, efavirenz, and teno

112 er inflammation in PWH receiving suppressive antiretrovirals, deserving targeted diagnosis and interv

113 At the time of elevated VL, 19% of cases had antiretrovirals detected in plasma, compared with 87% of

114 o TL change (global P = .019) but particular antiretrovirals did not (all P > .15).

115 ons in HIV-2 that confer resistance to other antiretrovirals did not confer cross-resistance to lenac

116 Use of antiretrovirals dually activity against HBV increased ov

117 Antiretrovirals during early HIV-1 infection modestly de

118 confirmed HIV infection who had not received antiretrovirals during this pregnancy.

119 immunosuppressants (e.g., cyclosporine) and antiretrovirals (e.g., protease inhibitors or nonnucleos

120 Little is known about how different antiretrovirals effect inflammation and monocyte activat

121 g the 2013 Controlling the HIV Epidemic With Antiretrovirals evidence summit in London, England, a gr

122 The second Controlling the HIV With Antiretrovirals evidence summit was held 22-24 September

123 As access to antiretrovirals expands under the WHO/Joint United Natio

124 were HIV-positive (n = 65 [64%]) had been on antiretrovirals for a median duration of 8.3 years (IQR,

125 Despite the recent success of antiretrovirals for HIV prevention, additional, more eff

126 By contrast, provision of antiretrovirals for HIV was not affected.

127 tivirals purposely directed against HHV8 and antiretrovirals for HIV-uninfected people are anticipate

128 hanisms of action and chemical structures to antiretrovirals for human immunodeficiency virus (HIV) i

129 The efficacy of short-course antiretrovirals for PMTCT in Africa is estimated at 50%.

130 people with HIV to prevent transmission, and antiretrovirals for pre-exposure prophylaxis.

131 The use of antiretrovirals for preexposure prophylaxis (PrEP) among

132 tion of children who were HEU and exposed to antiretrovirals for six UNAIDS regions and 21 HIV high-b

133 d for access to resistance testing and newer antiretrovirals for the optimal management of third-line

134 es, including XMRV, and the off-label use of antiretrovirals for the treatment of CFS does not seem j

135 y in HIV type 1-infected women not requiring antiretrovirals for themselves could control maternal vi

136 being considered as partners for long-acting antiretrovirals for use in therapy or prevention of HIV

137 HIV) has driven novel interventions, such as antiretrovirals, for pre-exposure prophylaxis.

138 s in the preclinical development of novel LA antiretrovirals formulations and delivery systems are su

139 PrEP with antiretrovirals has beneficial effects on early SHIV inf

140 but a link between endothelial function and antiretrovirals has not been established.

141 The introduction of antiretrovirals has resulted in a demographic shift with

142 Although antiretrovirals have been noted to favorably alter the c

143 ents treated with anti-TB therapy but not on antiretrovirals (historical control; Group 3).

144 fic factors and outcomes such as exposure to antiretrovirals, HIV progression, hospitalizations, and

145 seroconversion to receive either 36 weeks of antiretrovirals (immediate treatment [IT]) or no treatme

146 fants born from women taking a wide range of antiretrovirals in 4 pharmacovigilance databases (WHO Vi

147 fants born from women taking a wide range of antiretrovirals in 4 pharmacovigilance databases.

148 sistance to newer antiretrovirals and to all antiretrovirals in a class was uncommon.

149 those relating to the investigation of novel antiretrovirals in adolescents and pregnant and lactatin

150 nd KABC-II for children of mothers on triple antiretrovirals in both the ante-partum and post-partum

151 Concentrations of antiretrovirals in hair are associated with virologic ou

152 increased CD4 count when combined with other antiretrovirals in HTE PWH.

153 us one step closer toward using long-acting antiretrovirals in humans.

154 ation of pharmacokinetic and safety data for antiretrovirals in neonates.

155 Coadministration of methadone with antiretrovirals in patients with HIV may pose particular

156 Late initiation of antiretrovirals in pregnancy is associated with increase

157 l of ART efficacy (Prospective Evaluation of Antiretrovirals in Resource Limited Settings [PEARLS]).

158 articipants of the Prospective Evaluation of Antiretrovirals in Resource-Limited Settings trial, infl

159 re compared on pre-ART DRMs and detection of antiretrovirals in stored plasma.

160 ciency virus (HIV)-infected adults receiving antiretrovirals in sub-Saharan Africa.

161 Effective concentrations of antiretrovirals in the female genital tract (FGT) are cr

162 Women who had previously taken antiretrovirals in the past were excluded (up to 14 days

163 roviral therapy (ART) if they had detectable antiretrovirals in their blood or reported taking ART.

164 n the immune status following treatment with antiretrovirals, in rare cases the brain can become a ta

165 The number of antiretrovirals included in the ART regimen does not see

166 New studies are evaluating whether different antiretrovirals, including dapivirine, rilpivirine, mara

167 4 (58%) had previously received five or more antiretrovirals, including screening antiretrovirals, an

168 anding of how HIV-1 can evolve resistance to antiretrovirals, including the potent INSTIs, in the abs

169 vely stable virus loads before initiation of antiretrovirals, indicating feasibility of assessing HIV

170 The recent successes in transforming native antiretrovirals into lipophilic and hydrophobic prodrugs

171 the conduct of clinical DDIs studies with LA antiretrovirals is challenging.

172 Testing for resistance to antiretrovirals is considered to be standard of care and

173 mes for all MSM is crucial, since the use of antiretrovirals is foundational to optimising HIV care a

174 The current management of antiretrovirals is increasingly complex because of the l

175 irus (HIV)-positive patients treated with <3 antiretrovirals is unknown.

176 We investigated the potential roles of antiretrovirals, isoniazid, pharmacogenetics and other f

177 -1 infection has pivoted towards long-acting antiretrovirals (LA-ARVs).

178 ions of all vitamins except thiamin, whereas antiretrovirals lowered concentrations of nicotinamide,

179 s that effectively targeting the kidney with antiretrovirals may be critical for patients who are ser

180 dies (bNAbs) with long-acting small-molecule antiretrovirals may offer an alternative to daily oral t

181 Our findings suggest that specific antiretrovirals may potentially impact the risk of futur

182 ovides mechanistic clues to why early use of antiretrovirals may prove beneficial.

183 Here, we show that this choice of antiretrovirals may still cause a bias of pre-integratio

184 %/1%; 87% with HIV RNA <50 copies/mL; 99% on antiretrovirals; median CD4 count: 489 cells/microL; HCV

185 We show that antibodies and antiretrovirals mediate preexposure protection in this m

186 of HIV entry is needed for testing candidate antiretrovirals, microbicides, and vaccines.

187 ney disease was modest, treatment with these antiretrovirals might result in an increasing and cumula

188 eractions between antituberculosis drugs and antiretrovirals needs to be investigated.

189 Despite increasing use of antiretrovirals, no clear reduction in ESLD risk was obs

190 adverse events at least possibly related to antiretrovirals occurred in 30 (7%, 95% CI 5-10) of 438

191 quisition risks, such as approaches based on antiretrovirals, offer promise for controlling the expan

192 n to antiretrovirals, the negative effect of antiretrovirals offset the positive effect of LNSs for a

193 pact of pre-exposure prophylaxis (PrEP) with antiretrovirals on breakthrough HIV or SHIV infection is

194 Long-term effects of antiretrovirals on endothelial function may play an impo

195 ginning treatment, to investigate effects of antiretrovirals on lymphocyte and sperm chromosomes and

196 d individuals; however, the direct effect of antiretrovirals on virus replication in brain parenchyma

197 ssigned to receive antiretrovirals and LNSs, antiretrovirals only, LNSs only, or a control.

198 Patients on potentially nephrotoxic antiretrovirals or at high risk of chronic kidney diseas

199 s not appear to be related to patient use of antiretrovirals or to HIV-1 plasma RNA, cellular RNA, or

200 tion-based sequencing, to select appropriate antiretrovirals, plasma viral load monitoring, and inter

201 e measured in 18 patients receiving standard antiretrovirals plus 5-day courses of sc IL-2 (3-18 MIU/

202 ane, and oregano oil is a safe supplement to antiretrovirals, potentially delaying disease progressio

203 We adjusted analyses for time on antiretrovirals, pre-antiretroviral BMI, demographics, g

204 The primary objective was to use antiretrovirals (raltegravir, etravirine, and ritonavir-

205 chieved controlled release rates of multiple antiretrovirals ranging from mug/d to mg/d by altering t

206 14.0], P = .007), and the number of previous antiretrovirals received (HR = 1.2 per additional drug,

207 which patients with one or two fully active antiretrovirals remaining received oral fostemsavir (600

208 Younger people and those receiving fewer new antiretrovirals require careful monitoring.

209 cted patients treated early with combination antiretrovirals respond favorably, but not all maintain

210 l antioxidants (like mito-Tempo) and certain antiretrovirals resulted in the reversal of the effects

211 orded CD4 counts, receipt of prophylaxis and antiretrovirals, sensitivity and specificity of clinical

212 We used data from the Antiretrovirals, Sexual Transmission Risk and Attitudes

213 quity-focused Implementing Long-Acting Novel Antiretrovirals study evaluated feasibility, acceptabili

214 Long-acting injectable antiretrovirals such as rilpivirine (RPV) could promote

215 ide-based analogues, not normally considered antiretrovirals, such as the anti-herpes drugs Aciclovir

216 slope value among different classes of known antiretrovirals, suggesting a dose-dependent, cooperativ

217 With or without concomitant antiretrovirals, sustained virologic response rates were

218 e virus decrease strongly in the presence of antiretrovirals tenofovir and efavirenz whereas infectio

219 Thus, there is a need to identify antiretrovirals that act on viral life cycle stages not

220 , there is an urgent need for development of antiretrovirals that act on virus life cycle stages not

221 These data support the development of antiretrovirals that antagonize Vif and thereby enable e

222 ment in patients with HIV are needed, as are antiretrovirals that are without vascular risk.

223 ravir and rilpivirine are 2 long-acting (LA) antiretrovirals that can be administered intramuscularly

224 results suggest that short-term therapy with antiretrovirals that fail to penetrate the blood-cerebro

225 d logistic regression to identify individual antiretrovirals that were associated with first occurren

226 rotease inhibitors (PI), a critical class of antiretrovirals that will be used in up to 2 million ind

227 ; 24% with previous exposure to short-course antiretrovirals), the median time of follow-up from VS w

228 nfer broad resistance to multiple classes of antiretrovirals, the fold resistance is ~2 logs higher f

229 tiviral activity but, as with small-molecule antiretrovirals, the issues of viral escape and resistan

230 When LNS was given in addition to antiretrovirals, the negative effect of antiretrovirals

231 Because PrEP is based on antiretrovirals, there is considerable concern that it c

232 d benefits of adding potentially nephrotoxic antiretrovirals to a treatment regimen and would identif

233 netic background, clinical risk factors, and antiretrovirals to chronic kidney disease (CKD) is unkno

234 The widespread introduction of effective antiretrovirals to control HIV by restoring immunocompet

235 lts with HIV who had not previously received antiretrovirals to four groups (2:2:2:1).

236 ourse outcomes; defining the contribution of antiretrovirals to health disparities; identifying clini

237 dy randomized 346 pregnant women with HIV on antiretrovirals to PCV-10, PPV-23, or placebo at 14-34 w

238 Pre-exposure prophylaxis (PrEP), the use of antiretrovirals to prevent HIV acquisition, has shown pr

239 ic health include male medical circumcision, antiretrovirals to prevent mother-to-child transmission,

240 The use of antiretrovirals to reduce the incidence of human immunod

241 e ART can appropriately allocate more costly antiretrovirals to those with greater levels of HIV drug

242 in the Cambodian Early vs Late Initiation of Antiretrovirals trial (CAMELIA) in Cambodia.

243 cohort of HIV-infected pregnant women not on antiretrovirals, urinary CMV shedding was a significant

244 These findings are relevant for optimizing antiretrovirals used for biomedical HIV prevention in wo

245 Many antiretrovirals used in Brazil are produced domestically

246 Whether or not the association between some antiretrovirals used in HIV infection and chronic kidney

247 We report differential effects of antiretrovirals used in the treatment of HIV upon endoth

248 line ART and trough plasma concentrations of antiretrovirals were also reported post-BS.

249 eatment of HIV-seropositive individuals with antiretrovirals were published in The Lancet in April 19

250 Authorized antiretrovirals were tenofovir, emtricitabine, efavirenz

251 Minimum manufacturing costs of antiretrovirals were US$0.2-$2.1 per gram.

252 The antiretrovirals were zidovudine/lamivudine and nelfinavi

253 29 (fostemsavir) represents a novel class of antiretrovirals which target human immunodeficiency viru

254 ts should start with the control of HIV with antiretrovirals, which frequently results in KS regressi

255 we demonstrated the ability to co-formulate antiretrovirals with contraceptives in an ISFI that is w

256 e (Gardasil9(R)MSD) in WWH (15-40 years), on antiretrovirals with HIVRNA<400cp/ml; enrollment 2018-20

257 ions were then compared with actual costs of antiretrovirals with similar structures.

258 >350 cells/ microL (7 of whom were receiving antiretrovirals) with Haemophilus ducreyi.

259 assays is important, but widening access to antiretrovirals-with or without laboratory monitoring-is

260 aining 101 children) received treatment with antiretrovirals within the first 3 months of life.

261 sed in utero to human immunodeficiency virus antiretrovirals, yet their safety is often not well char